Bristol inks $2.4B deal for Medarex

Bristol-Myers Squibb agreed to buy Medarex for about $2.4 billion to double its pipeline of experimental biological drugs, including one nearing U.S. approval for skin cancer. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.